Jiangsu Hengrui Pharmaceuticals

CompanyChina

Jiangsu Hengrui Pharmaceuticals develops one asset, in phase 3 (ribupatide in obesity). Mostly peptide acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and GLP1R; based in China.

1
Asset
Furthest stage: Phase 3; 0
Trials: 3
Signals

Pipeline

1

ribupatide
Dual GLP-1 and GIP receptor agonist for metabolic disorders and weight loss
Phase 3, Peptide, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, obesity, obesity with diabetes

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms7
Deals16
Signals12
Similar companies6

Papers

HRS-7535 improved blood-sugar control in type 2 diabetes
Diabetologia, 15 Oct 2026
Efficacy and Safety of Oral Ribupatide (HRS9531) in Adults with Obesity: A Phase 2 Trial
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
Efficacy and Safety of a Novel Dual GLP-1/GLP Receptor Agonist in Chinese Overweight or Obese Adults without Diabetes
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes—Up to 52-Week Treatment
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
Efficacy and Safety of a Novel Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist (HRS-7535) in Type 2 Diabetes Mellitus Patients Inadequately Controlled by Metformin
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 Tablet, an Oral Dual GLP-1/GIP Receptor Agonist, in Healthy Participants—A Phase 1 Study
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
Efficacy and Safety of a Novel Dual GLP-1/GIP Receptor Agonist in Participants with Type 2 Diabetes Mellitus Up to 32 Weeks
ADA Scientific Sessions 2025 abstract, 13 Jun 2025